—A Webinar from Decision Resources
Based on our European Physician & Payer Forum report entitled How Will New Entrants Alter the Biologics Landscape in Ankylosing Spondylitis and Psoriatic Arthritis? A European Physician and Payer Perspective, Decision Resources is offering this exclusive webinar. Because this presentation will feature major report findings, it is ONLY available to purchasers of this report.
Please contact us to learn how you can purchase this report and attend the webinar.
The approval of tumor necrosis factor-alpha (TNF-α) inhibitors filled a critical unmet need in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) given the limited efficacy of conventional disease-modifying antirheumatic drugs in treating these diseases. Four TNF-α inhibitors are currently marketed for both indications, with a fifth—UCB/Otsuka’s Cimzia—in Phase III trials for both indications. The lack of targeted immune therapies other than TNF-α inhibitors in PsA and AS creates an opportunity for drug developers, which is evidenced by late-stage candidates with alternative mechanisms of action that are in development for both indications. The emergence of these agents, most notably Janssen Biotech/Janssen-Cilag’s interleukin-12 and -23 (IL-12/23) inhibitor Stelara and Celgene’s phosphodiesterase-4 inhibitor apremilast for PsA and Novartis’s IL-17 inhibitor secukinumab for AS, has set the stage for treatment to evolve beyond TNF-α inhibition. Recent changes to guidelines have complicated analysis of the market opportunity for biologics in the treatment of axial spondyloarthritis (SpA), which includes both AS and the related condition undifferentiated or pre-radiographical axial SpA, considered to be a possible precursor to AS. The 2010 guidelines from the Assessment in SpondyloArthritis International Society (ASAS) recommend use of TNF-α inhibitors in patients with either one of these conditions, even in the absence of European labelling for these agents in undifferentiated axial SpA.
This report explores physician expectations and payer attitudes regarding current use of biologics in PsA, AS and undifferentiated axial spondyloarthritis, differences in at what point in the treatment algorithm biologics are prescribed for each indication, projected uptake for Stelara in PsA, patient groups in PsA likely to be targeted by physicians for apremilast treatment, and the drug attributes surveyed rheumatologists believe will be key to driving uptake of secukinumab in AS. The report is based on a survey of 251 rheumatologists in the EU5 and on interviews with 15 European payers and payer-advising key opinion leaders with influence at a national, regional and/or hospital level.
This webinar, presented by Decision Resources Therapeutic Area Director Madhuri Borde, Ph.D., will answer the following questions:
- What funding and reimbursement barriers govern access to biologics in PsA, AS and undifferentiated axial SpA? What percentage of surveyed rheumatologists’ patients with each disease is considered to be candidates for biologics treatment, and how does this compare with the percentage of patients receiving biologics? What agents do patients typically need to fail before moving to a biologic in peripheral-predominant PsA, axial-predominant PsA, AS and undifferentiated axial SpA, and how does this vary by country?
- Which agents will dominate first- and second-line biologic treatment choice in PsA in 2013, and how does this vary by country? Are there differences in biologic prescribing by line depending on if a patient has peripheral-predominant or axial-predominant PsA? How do surveyed rheumatologists expect biologic treatment rates in AS and undifferentiated axial SpA to change between 2011 and 2013, and what degree of uptake do surveyed rheumatologists expect for Simponi and Cimzia in axial SpA treatment?
- What efficacy advantages do surveyed rheumatologists consider the most important for driving prescribing of Stelara and secukinumab in PsA and axial SpA? What percentage of surveyed rheumatologists’ PsA and axial SpA patients will be treated with each therapy?
Dr. Borde will conduct a live Q & A session after the presentation.
Filling Critical Unmet Need in Psoriatic Arthritis and Ankylosing Spondylitis: European Physician and Payer Insights on New Market Entrants
January 26, 2012 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Madhuri Borde, Ph.D., is a therapeutic area director in the Immune and Inflammatory Disorders group at Decision Resources. Dr. Borde has authored market research reports covering a wide array of topics, including rheumatoid arthritis, psoriasis, TNF-alpha inhibitors, asthma and multiple sclerosis. She received a Ph.D. from Harvard University, where she researched transcription factors involved in regulating autoimmunity and identified a novel transcriptional complex required for regulatory T-cell function and development. Dr. Borde graduated with honors from the University of California at Berkeley with a degree in molecular and cellular biology.|
For more information about our products and services, please contact us using the information below.
North America Europe Japan |
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2012 Decision Resources, LLC. All rights reserved.
